**FOI 22/1197 – OXFORD ASTRA-ZENECA COVID VACCINE APPLICATION - adventitious virus assays**

**6 January 2023**

**MHRA RESPONSE**

Dear

Thank you for your information request, dated 14 December 2022, where you asked the following information:

**"Did the Oxford Astra Zeneca Covid vaccine application for Temporary Authorisation include proof that their product had undergone adventitious virus assays? In the event that the answer to that question is no, could you please explain why that was not required prior to licensing?"**

We are pleased to provide you with the information requested, see below.

Yes, the Oxford Astra Zeneca Covid vaccine application for Temporary Authorisation included proof that their product had undergone adventitious virus assays. Comprehensive data was provided by AZ.

If you disagree with how we have interpreted the Freedom of Information Act 2000 with regards to your request, you can ask for the decision to be reviewed. The review will be carried out by a senior member of the Agency who was not involved with the original decision.

If you have a query about the information provided, please reply to this email.

Please remember to quote the reference number above in any future communications.

If you were to remain dissatisfied with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted at:

Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Yours sincerely

MHRA Customer Service Centre

Medicines and Healthcare products Regulatory Agency
10 South Colonnade, Canary Wharf, London E14 4PU